Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
about
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionPrevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupMolecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemiaBeyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaImpact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology GroupMaintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.Spotlight on histamine dihydrochloride in acute myeloid leukaemia.Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis.NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study.The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupWT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology groupBiology, risk stratification, and therapy of pediatric acute leukemias: an update.Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.Recent advancements of flow cytometry: new applications in hematology and oncology.Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international studySurvival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplantSuperior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemiaDifferences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States.
P2860
Q24187297-AC1388F9-6A0C-4225-BACB-F4218ADC9568Q24187927-CD4AA207-BBC7-4278-87AC-5D15483F390AQ24202630-A745439E-99DD-4D91-B10C-943849C07045Q24602856-CAF69AFE-C420-481B-BAEA-A4765D3EB9D7Q24657303-C4CBBF63-657A-4D1C-9494-05CF81C2ECECQ26781328-C7D4B214-EC7A-41C6-BA86-EB9633647F1BQ26992280-8D3FD1D2-0955-46C4-A41E-3B09C252C122Q27005960-3A31F3DB-D4E4-4979-A5E8-63B12ED4BA44Q28755379-52D8E29B-5CB6-43C3-965A-CFBFB2725AE7Q30249246-F5C5308F-9FCA-4CAF-AD9E-59A491BD2B28Q30979681-6170235F-B589-4979-B63A-177C6F73B855Q33380148-3150346B-88B0-44A1-879E-D408D732790CQ33394612-6C28773D-ED71-4A3C-80E3-FC92520A8CA2Q33400806-0740C770-DB22-48BA-B88D-32E7D1D2309FQ33555627-31698484-CBB4-4BC4-94F7-2A35565B1F72Q33710760-2B1D9B61-0616-4734-86F9-66A5A624C728Q33732434-D22259DA-B04D-44A0-BBC3-CA095C6EB754Q33881750-FF51CE81-460B-4185-9CF8-5013710FD06FQ34043467-DF233703-C166-49CA-88F4-F56D78531FCEQ34052581-DE68C6CD-0D05-4AA9-BBF2-E8F60BD708C9Q34062534-EBB86F7F-CF4E-4B8F-8553-C492740A9CBCQ34080807-AA1F0E3A-BC14-4774-A96F-CD2C8F3C620EQ34172042-80365771-8603-475D-9036-B41ED2D25364Q34278721-CD134BF8-C02D-4BA9-8EAF-EE79C3A5DC20Q34318490-64FA750B-78CA-4603-953E-F7134F8ACB9CQ34325487-32C8E03A-3572-4C14-931B-DD00284370A3Q34344493-A56F63B4-139F-4292-AF31-4B65DAD028AAQ34585047-04968371-1152-40B4-8172-13E247DF33B4Q34667832-7D569739-2F8D-43F3-936B-72A316B89301Q34764504-20EB8A35-6619-4609-98C9-E34EB4561CEEQ35048344-8F95B824-0CAE-455D-8FDD-E4DD02E65772Q35059549-51868143-94CE-425E-8207-09A3D011F7BFQ35114704-CB71727B-6E36-480C-AF94-241BFEE94826Q35127974-5BABF032-3C48-403D-8FEB-D6D952208345Q35189037-97E00107-A9AA-4265-8F63-9FBD75BFDDBFQ35190576-883421C5-05B2-4FA8-AC86-763AD2B61A6BQ35209900-D047A99D-D950-4287-BB9E-CCC1EF46844DQ35210494-A07F7085-F70D-449E-9B6B-D27CE7DDF217Q35430146-97D1E1BC-B002-445E-8C51-9C9719DBDAA7Q35530413-2FCCD86F-8AD2-49A6-AA05-3BFC81AD1F20
P2860
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@ast
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@en
type
label
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@ast
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@en
prefLabel
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@ast
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@en
P2093
P2860
P1433
P1476
Outcomes in CCG-2961, a childr ...... the children's oncology group.
@en
P2093
Beverly J Lange
Carola Arndt
Dorothy R Barnard
Franklin O Smith
James Feusner
Kathryn Dusenbery
Kevin Shannon
Margie Weiman
Patricia Dinndorf
Robert B Gerbing
P2860
P304
P356
10.1182/BLOOD-2007-04-084293
P407
P577
2007-11-13T00:00:00Z